ARE logo

Alexandria Real Estate Equities

ARE · What the business does, what can go wrong, and how options sellers approach it

What it does

Alexandria Real Estate Equities is a real estate investment trust (REIT) that owns and operates lab and office space for life science companies, including biotechnology and pharmaceutical firms, research institutions, and some agricultural and technology tenants.

Its properties cluster in research hubs such as Greater Boston, the San Francisco Bay Area, San Diego, Seattle, New York City, Maryland, and North Carolina's Research Triangle. It also develops and redevelops specialized lab buildings.

How it makes money

The main source of revenue is rent. Tenants usually sign multi-year leases, and many leases include scheduled rent increases and pass-through of operating costs. The company also earns income by developing new projects and leasing them, and it may sell certain assets to raise capital. As a REIT, it generally must distribute most of its taxable income to shareholders.

Why investors own it

  • Exposure to the life science industry through real estate rather than through drug development outcomes.
  • Specialized lab buildings are costly to build and hard to replicate, which can support tenant retention.
  • A dividend-oriented profile, typical of REITs.
  • Clustering of properties near universities, talent, and funding sources.

What can go wrong

  • Biotech funding can swing with capital markets, and tenants that depend on outside funding may cut back on space.
  • Oversupply of new lab space in a market can weigh on occupancy and rents.
  • Rising interest rates raise borrowing costs and can pressure real estate valuations.
  • Development projects can run late or over budget, or lease up slowly.
  • Tenant concentration in one industry and in a few regions reduces diversification.

What to watch

  • Occupancy rates
  • Leasing volume and rent changes on renewed leases
  • Funds from operations (FFO) per share
  • Development pipeline and timing of deliveries
  • Debt levels and upcoming maturities
  • Dividend coverage
  • Biotech funding trends and venture capital activity
  • Interest rate direction

Options income angle

Options on ARE are listed across several expirations, but liquidity is usually thinner than for the most heavily traded stocks, so spreads can be wider on far-from-the-money strikes. Implied volatility tends to rise around earnings, interest rate shifts, and biotech funding news.

One caution for premium sellers: REITs can fall sharply when rates or sentiment turn, and a covered call caps upside while leaving most of the downside. Early assignment on short calls is also more likely just before ex-dividend dates.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed January 26, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Alexandria Real Estate Equities, a REIT (real estate investment trust) that owns life science laboratory campuses, reported net income attributable to common stockholders of $(1,438.0) million for 2025, against $309.6 million in 2024. The swing came mainly from $2.20 billion of real estate impairments (write-downs of property values). Occupancy fell to 90.9% from 94.6%, management projects approximately 88.5% for the end of 2026, and the quarterly dividend was cut by 45%.

How the business did

  • Revenue and earnings: Total revenues were $3.03 billion, down 2.9% from $3.12 billion, largely because of property sales. Excluding dispositions completed after January 1, 2024, revenues would have increased by 2.3%. Funds from operations (FFO, a REIT earnings measure that adds back real estate depreciation), as adjusted, was $9.01 per share versus $9.47.
  • Properties held in both years: Same property net operating income decreased by 3.5%, and increased by 0.9% on a cash basis. Average occupancy was 92.5% versus 95.2%.
  • Leasing: Leasing volume was 4.2 million RSF (rentable square feet). Rental rates on renewals and re-leasing rose 7.0%, or 3.5% on a cash basis.
  • Cash and capital: Net cash provided by operating activities was $1.41 billion versus $1.50 billion. Dispositions and sales of partial interests totaled $1.81 billion. General and administrative expenses fell 30.5% to $117.0 million.
  • Unusual items: Of the impairments, $910.7 million related to assets designated as held for sale. A realized loss of $103.3 million on one investment transaction also affected results.

Risks specific to this company

  • Life science oversupply: Available life science space in the top three markets rose to approximately 29% in 2025 from approximately 4% in 2021, while tenant demand fell by more than 60%. The filing ties this to slower leasing, lower rents and higher concessions.
  • Government and policy exposure: Tenants and venture investments depend on NIH funding, FDA approvals, drug pricing and tariffs. The filing describes 2025 FDA and NIH layoffs, a proposed 15% cap on NIH indirect cost reimbursements, and a partial government shutdown that lasted for 43 days.
  • Dependence on asset sales: The 2026 plan assumes approximately $2.90 billion of dispositions at the midpoint to fund construction and repay debt, including $650 million of notes maturing in 2026. If sales fall short, the company may repay less debt or borrow more.
  • Joint venture partner rights: In six consolidated joint ventures with aggregate noncontrolling interests of approximately $1.17 billion, partners had the ability as of December 31, 2025 to force a sale or start a buy/sell process.
  • Geographic concentration: Nearly 33% of properties are in California. The filing cites earthquake, wildfire and PG&E power shutoff risk in the San Francisco Bay Area.
  • Dividend and venture portfolio: The board may reduce or suspend the dividend further. The $1.50 billion non-real estate investment portfolio can be hard to sell, and it produced an investment loss of $56.3 million.

What management is watching

  • 2026 guidance: FFO per share of $6.25 to $6.55, with a midpoint of $6.40. Same property net operating income is guided to (9.5)% to (7.5)%, and cash rental rate changes to (12.0)% to (4.0)%.
  • Capital plan: Construction spending of $1.75 billion at the midpoint, funded by dispositions, $525 million of net cash from operations after dividends, and a debt reduction of approximately $1.68 billion.
  • Interest costs: Interest expense is expected to rise to approximately $255 million from $227 million, as capitalized interest (borrowing costs added to project cost) falls to approximately $250 million.
  • Credit metrics: The target for net debt and preferred stock to Adjusted EBITDA is 5.6x to 6.2x for the annualized fourth quarter of 2026. The first-quarter 2026 ratio is expected to run approximately 1.0x to 1.5x above the fourth-quarter 2025 level of 5.7x.
  • Leasing and strategy: Key lease expirations of 1.2 million RSF are expected to sit vacant for 6 to 24 months, and four projects are under business strategy evaluation. Management points to its Megacampus platform, which supplied 78% of annual rental revenue.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 26, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Alexandria Real Estate Equities reported a net loss attributable to common stockholders of $(638.5) million for the three months ended September 30, 2026. The loss was driven by $637.9 million of real estate impairment charges (write-downs) on assets held for sale. Funds from operations, as adjusted (a REIT cash earnings measure), fell to $264.4 million from $377.8 million a year earlier. The company kept its full-year per-share guidance midpoint at $6.40 and narrowed the range.

How the business did

  • Results: Diluted net loss per share was $(3.74), against $(1.38) a year earlier. For nine months, the net loss was $(351.4) million, against $(356.1) million. A $363.1 million gain on early extinguishment of debt, from February bond repurchases at a discount, helped that period. Funds from operations, as adjusted, were $856.5 million for nine months, against $1,166.3 million.
  • Property performance: Same property net operating income (profit at properties owned throughout both periods) decreased by 6.7% for the quarter and 9.2% for nine months. Average occupancy at those properties was 88.1%, against 91.7%, mainly because of previously disclosed lease expirations. Operating occupancy was 87.1%, up from 86.9% at June 30, 2026.
  • Leasing: Total leasing volume surpassed 1.2 million RSF (rentable square feet), the highest since the fourth quarter of 2024. Rents on renewed and re-leased space changed by (2.4)%.
  • Cash and capital: Net cash provided by operating activities for nine months decreased 20.5% to $0.88 billion, from $1.10 billion. The company declared a common dividend of $0.72 per share, consistent with the prior quarter. It issued $1.00 billion of 7.250% junior subordinated notes due 2057 in August. No shares have been repurchased under the $500.0 million program.

What management is watching

  • Guidance and leverage: Funds from operations per share, as adjusted, is guided to $6.38 to $6.42. Management targets net debt and preferred stock to Adjusted EBITDA of 5.6x to 6.2x for the fourth quarter, annualized, against 6.9x for the third quarter. The fixed-charge coverage target was lowered to 3.4x to 3.9x from 3.6x to 4.1x. Year-end operating occupancy is projected at approximately 87.0%.
  • Funding through asset sales: The 2026 guidance midpoint for dispositions and sales of partial interests is $1.90 billion, with $717 million completed. That includes the October sale of an approximately 29% interest in Campus Point by Alexandria for $475.0 million. Construction spending is guided to $1.75 billion at the midpoint. The company says price and timing of sales may be hurt by lower property valuations and higher interest rates.
  • 2027 headwinds: Key lease expirations with expected downtime total 1.4 million RSF, with downtime of 9 to 24 months. Management expects 2027 same property net operating income to improve but stay negative. It also expects at least a similar reduction in funds from operations from potential tenant wind-downs (tenants failing or leaving).
  • Projects under review: Three redevelopment projects totaling 667,002 RSF are being evaluated. At 311 Arsenal Street, a shift to advanced technology use reduces future spending by approximately $220 million. A pending sale of 421 Park Drive would reduce it by approximately $136 million.

Follow ARE in Kortex

The Kortex app shows ARE's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.